36 Background: ASCO guidelines recommend cancer survivors be evaluated, treated, & reassessed for depression & anxiety along the trajectory of care. To meet these guidelines, UT Southwestern Moncrief Cancer Institute instituted an integrated approach to mental health screening, assessment, & navigation called MH-SCAN. (Andersen, BL, Rowland, JH, Somerfield, MR. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation.J Onc Prac, 2015. 11(2): p. 133-134.) Methods: MH-SCAN uses the Vital Sign6 (VS6) program, a web-based application to screen & monitor psychiatric symptoms, and to give feedback regarding measurement-based care (MBC). Measures are repeated at 2-week intervals when possible for those who need treatment. Our implementation process, including training & workflows, will be reviewed. Results: Patients (N = 415) enrolled from 9/1/15 to 8/1/16 in our community-based Survivorship Program (see table) were screened using VS6, of which 119 reported symptoms indicating potential depression. Over 90% of that subset reported moderately severe symptoms and 87% endorsing comorbid symptoms of anxiety. Approximately 60% of the original sample completed reassessment within 4 weeks. Over half continued to endorse significant depressive symptoms, as well as suicidal ideation and comorbid anxiety. Conclusions: Implementing ASCO recommendations for mental health screening, assessment, and treatment adherence, while challenging, is feasible. Our preliminary data underscores its importance among survivors. The MH-SCAN protocol provides a useful approach to implementing screening guidelines efficiently and effectively, thus addressing mental health comorbidities within oncology and primary care.[Table: see text]
309: Expanding the Cystic Fibrosis Foundation’s mental health screening guidelines: Early childhood behavioral health assessment for children with cystic fibrosis aged 4 to 11
